Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gynaecological sarcomas.

Stefan Sleijfer1, Caroline Seynaeve, Jaap Verweij

  • 1Department of Medical Oncology, Erasmus University Medical Centre, Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands. s.sleijfer@erasmusmc.nl

Current Opinion in Oncology
|September 1, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Challenges and Potential Solutions to Advance Global Cancer Drug Development.

Therapeutic innovation & regulatory science·2026
Same author

Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.

Nature communications·2025
Same author

Empowering effective biomarker-driven precision oncology: A call to action.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022
Same author

A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.

Clinical cancer research : an official journal of the American Association for Cancer Research·2021
Same author

Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study.

NPJ breast cancer·2021
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Gynaecological sarcomas are rare tumors with diverse subtypes, primarily uterine leiomyosarcomas and endometrial stromal sarcomas. Effective management requires specialized multidisciplinary teams due to treatment complexity.

Area of Science:

  • Gynecologic Oncology
  • Pathology
  • Surgical Oncology

Background:

  • Gynaecological sarcomas represent a rare and diverse group of soft tissue tumors.
  • Uterine leiomyosarcomas and endometrial stromal sarcomas are the most prevalent subtypes within the female reproductive tract.
  • Recent classifications distinguish these from mixed Müllerian tumors, now considered carcinomas.

Purpose of the Study:

  • To provide a comprehensive review of gynaecological sarcomas.
  • To outline current management strategies for these rare tumors.
  • To discuss future perspectives in the field.

Main Methods:

  • Literature review of gynaecological sarcomas.
  • Analysis of current treatment modalities.
  • Discussion of emerging research and therapeutic targets.

Related Experiment Videos

Main Results:

  • Identification of common and rare subtypes of gynaecological sarcomas.
  • Emphasis on the distinct nature of sarcomas compared to carcinomas.
  • Highlighting the necessity of multidisciplinary team-based care for optimal patient outcomes.

Conclusions:

  • Gynaecological sarcomas are distinct from carcinomas, necessitating tailored treatment approaches.
  • The rarity and complexity of these tumors underscore the importance of expert management.
  • Advancements in understanding pathogenesis are anticipated to drive novel therapeutic developments.